Because serum is a source of fatty acids, we further assessed differences in the response of prostate cancer cells to FASN inhibitors by carrying out experiments in reduced serum (1%) medium, thus reducing the availability of fatty acid. The gene discussed is FASN; the disease is prostate carcinoma.